



Fleet
Laxative
SALINE enema
ready, soft, fast
latex-free
Easy to use

DenTek
90 COUNT
Comfort Clean
FLOSS PICKS
with Advanced Fluoride Coating

Clear eyes
PURE
relief
FOR DRY EYES
PRESERVATIVE FREE

Prestige Brands

William Blair Growth Stock Conference
June 13, 2018

Safe Harbor Disclosure

This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company’s expected financial performance, including revenue growth, adjusted EPS, and adjusted free cash flow; the Company’s expected leverage and ability to de-lever; the market position, expected growth and consumption trends for the Company’s brands; the impact of brand-building and product innovation and the related impact on the Company’s revenues; the Company’s planned pursuit of M&A opportunities; the ability to create long-term shareholder value; the impact of retailer destocking; and the Company’s expectations regarding improved warehousing and freight costs. Words such as “trend,” “continue,” “will,” “expect,” “project,” “anticipate,” “likely,” “estimate,” “may,” “should,” “could,” “would,” and similar expressions identify forward-looking statements. Such forward-looking statements represent the Company’s expectations and beliefs and involve a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include, among others, general economic and business conditions, regulatory matters, competitive pressures, supplier issues, disruptions to distribution, unexpected costs or liabilities, and other risks set forth in Part I, Item 1A. Risk Factors in the Company’s Annual Report on Form 10-K for the year ended March 31, 2018. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation. Except to the extent required by applicable law, the Company undertakes no obligation to update any forward-looking statement contained in this presentation, whether as a result of new information, future events, or otherwise.

All adjusted GAAP numbers presented are footnoted and reconciled to their closest GAAP measurement in the attached reconciliation schedules or in our May 10, 2018 earnings release in the “About Non-GAAP Financial Measures” section.

Contents

I. Who is Prestige Brands?

II. Value Creation Model

III. Financial Review and Outlook

Attendees

Ron Lombardi

Chairman & Chief Executive Officer

Christine Sacco

Chief Financial Officer

Phil Terpolilli

Director, Investor Relations

I. Who is Prestige Brands?

Compound W
WART REMOVER

Fleet

Summer's Eve

Dramamine

DenTek

LUDEN'S

**LITTLE
REMEDIES**

Efferdent
ANTI-BACTERIAL DENTURE CLEANSER

**Clear
eyes**

BC

Goody's

Chloraseptic
FAST ACTING

Nix
PERMETHRIN

eat the foods you love!
beano

Hydralyte

MONISTAT

Gaviscon
and it's gone

Debrox

FESS

Helping Consumers Care for Themselves

5+
Billion

eye drops per year



650
Million

throat drops for every cold season



17
Million

doses of pain relief per week




8
Million

infections treated annually



Source: Company records

Diversified Portfolio of Leading, Trusted Brands



Source: LTM Revenues
 Note: Excludes other OTC (less than 1%)

Our Portfolio of Invest-for-Growth OTC Brands

Power Core \$100MM+ Brands



Core




International



Source: IRI MULO+C-Store period ending March 25, 2018; Retail Dollar Sales


Five "Power Core" Brands Average Over \$150MM at Retail




- Leading brands well-positioned in evolving environment
- Execute brand-building playbook
- Continue to grow our categories and market share

Source: IRI MULO+C-Store (Retail Dollar Sales).

Platform Positioned for Long-Term Success




Leading Platform
in Unique OTC Aisle



Strong Brands
Across 8+
Categories



OTC Brands
Generate Solid,
Durable Cash Flows



History of
Share Gains
& Growth

II. Value Creation Model

Compound W
WART REMOVER

Fleet

Summer's Eve

Dramamine

DenTek

LUDEN'S

**LITTLE
REMEDIES**

Efferdent
ANTI-BACTERIAL DENTURE CLEANSER

**Clear
eyes**

BC

Goody's

Chloraseptic
FAST ACTING

Nix
PERMETHRIN

eat the foods you love!
beano

Hydralyte

MONISTAT

Gaviscon
and it's gone

Debrox

FESS

Proven, Consistent & Repeatable Strategy

#1

Invest for Growth

- Positioned for long-term 2% to 3% Organic growth
- Brand building to drive long-term success

#2

Cash Generation

- Industry-leading financial profile
- Best-in-class ongoing FCF generation
- Enables capital allocation opportunities

#3

Capital Deployment

- Completed 5 acquisitions since CY 2013
- Continue to seek strategic M&A
- Authorized \$50 million stock buyback completed

Proven, Consistent & Repeatable Strategy

#1

Invest for Growth

- Positioned for long-term 2% to 3% Organic growth
- Brand building to drive long-term success

Near-term Considerations

- Taking share vs. category and private label
- Unique proposition to retailers in changing retail landscape
- Destocking continues based on retailer productivity focus
- E-commerce remains an opportunity, not a threat

Long-term Positioning

- Category leading, trusted brands
- Continued portfolio growth via brand-building toolkit
- Innovation drives category growth
- Differentiated positioning against competitors



... With a Resilient Position in an Evolving Retail Environment

Category Leading, Trusted Brands

- #1 share brands represent ~60% of sales
- Brands drive long-term category growth



On Trend & Innovative

- Consumer driven innovation
- Aligned with macro-Health & Wellness trend



Retail Traffic Driver

- Need-based products sought by consumers
- Retail channel agnostic



E-Commerce Brand of Choice

- Channel remains an opportunity, not a threat
- Ongoing channel investments




... and Brand-Building That Drives Category Growth and Share Gains

Long-Term Brand-Building Toolkit

- Leverage portfolio's long-standing brand heritage with focused digital and content marketing
- Develop consumer insights to refine brand-building efforts
- Focus new product development on attractive opportunities that are key to category growth
- Capitalize on new channel development opportunities

Growing the Category and Outpacing Private Label

2017 Performance Consumption Growth*



Brand-Building Differentiates versus Private Label and Branded Competition

* IRI MULU Data as of calendar year-end 2017; Categories include those pertaining to PBH's core brands (SE, Monistat, BC / Goody's, Clear Eyes, DenTek, Dramamine, Beano, Fleet, Boudreaux's, Little Remedies, The Doctor's, Efferdent, Chloraseptic, Luden's, Debrox, Compound W, Nix)

BC & Goody's: Continuing Our Long-Term Brand Building Playbook

Brand Success Under Ownership

- Purchased two iconic brands in 2012
- 100+ year heritage in Southeast
- Expanded brand building investments



>25%
Growth Since
Acquisition

- Only powdered analgesic brands
- Expanded distribution
- Brand extensions into cough/cold with BC Sinus Launch
- Significant support at retail by leveraging strategic partnerships

New Packaging to be Launched in FY 19

Continued Innovation to Grow the Brand and the Category



Proven, Consistent & Repeatable Strategy

#2

Cash Generation

- Industry-leading financial profile
- Best-in-class ongoing FCF generation
- Enables capital allocation opportunities

Near-term Considerations


- Net Debt at March 31 of \$1,980 million; leverage ratio of 5.2x⁽⁴⁾ at end of FY 18
- Debt reduction of \$209 million in FY 18
- Re-financed portion of Term Loan with Senior Notes to mitigate impact of rising interest rates in March 2018

Long-Term Positioning


- High Free Cash Flow Generation
 - Portfolio drives high EBITDA margins
 - Strong FCF conversion (minimal capex, tax attributes)
- A&P reinvestment to drive top-line growth
- Maintain approximate mid-30s EBITDA margin target

Strong and Consistent Cash Flow Leads to Rapid De-Levering

Adjusted Free Cash Flow⁽³⁾⁽⁵⁾



Leverage Ratio⁽⁴⁾



Dollar values in millions.

* Peak leverage of 5.75x at close of the Insight Acquisition in September 2014

3 Key Drivers of Long-Term Shareholder Value

#3

Capital Deployment

- Completed 5 acquisitions since CY 2013
- Continue to seek strategic M&A
- Authorized \$50 million stock buyback completed



III. Financial Review and FY 19 Outlook

Compound W
WART REMOVER

Fleet

Summer's Eve

Dramamine

DenTek

LUDEN'S

**LITTLE
REMEDIES**

Efferdent
ANTI-BACTERIAL DENTURE CLEANSER

**Clear
eyes**

BC

Goody's

Chloraseptic
FAST ACTING

Nix
PERMETHRIN

eat the foods you love!
beano

Hydralyte

MONISTAT


Gaviscon
and it's gone

Debrox


FESS

Strategy Has Delivered Consistently Strong Financial Performance


Net Sales




Adjusted EBITDA⁽³⁾



Adjusted Free Cash Flow⁽³⁾



Adjusted EPS⁽³⁾



Dollar values in millions, except Adjusted EPS.

Strong Financial Performance in FY 18

Revenue of \$1,041 million, up 18.0% versus FY 17

Solid consumption growth of 2.9%⁽²⁾ outpaced revenue growth of 1.7%⁽¹⁾ pro forma for the acquisition of Fleet

Adjusted EPS of \$2.58⁽³⁾, up 8.9% versus FY 17

Continued to manage capital structure through re-financing and debt paydown

Adjusted Free Cash Flow of \$208 million⁽³⁾, up 5.7% versus FY 17

FY 19 Full Year Outlook: Staying the Strategic Course to Create Value

Top Line Trends

- Continue to gain market share with consumers and grow categories with retailers
- Prestige's portfolio of need-based brands continues to be well positioned for future long-term growth, despite macro headwinds at retail

Revenue

- Revenue growth of +0.5% to +1.5% (\$1,046 to \$1,056 million)
 - Expect consumption growth in excess of shipment growth
 - Revenue growth to be impacted by transition to new BC / Goody's packaging
 - Revenue growth concentrated in 2H FY 19


EPS

- EPS +15% to +18% (\$2.96 to \$3.04)
 - EPS growth concentrated in 2H FY 19 due to multiple timing factors
- Effective tax rate of approximately 26%, compared to prior rate of approximately 36%

Adjusted Free Cash Flow⁽³⁾

- Adjusted Free Cash Flow of \$215⁽³⁾ million or more

Continuing Our Long-Term Value Creation Strategy



Appendix

- (1) Organic Revenue Growth and Proforma Revenue Growth are Non-GAAP financial measures and are reconciled to the most closely related GAAP financial measure in the attached Reconciliation Schedules and / or our May 10, 2018 earnings release in the “About Non-GAAP Financial Measures” section.
- (2) Total company consumption is based on domestic IRI multi-outlet + C-Store retail dollar sales for the period ending 3-25-18 and net revenues as a proxy for consumption for certain untracked channels, and international consumption which includes Canadian consumption for leading retailers, Australia consumption for leading brands, and other international net revenues as a proxy for consumption.
- (3) Adjusted EBITDA, Adjusted EPS, Adjusted Free Cash Flow and Net Debt are Non-GAAP financial measures and are reconciled to their most closely related GAAP financial measures in the attached Reconciliation Schedules and / or in our May 10, 2018 earnings release in the “About Non-GAAP Financial Measures” section.
- (4) Leverage ratio reflects net debt / covenant defined EBITDA.
- (5) Adjusted Free Cash Flow for FY 19 is a projected Non-GAAP financial measure, is reconciled to projected GAAP Net Cash Provided by Operating Activities in the attached Reconciliation Schedules and / or in our May 10, 2018 earnings release in the “About Non-GAAP Financial Measures” section and is calculated based on projected Net Cash Provided by Operating Activities less projected capital expenditures plus payments associated with acquisitions less tax effect of payments associated with acquisitions.

Reconciliation Schedules

Organic Revenue Growth

| | Three Months Ended Mar. 31, | | Year Ended Mar. 31, | |
|--|-----------------------------|------------|---------------------|--------------|
| | 2018 | 2017 | 2018 | 2017 |
| <i>(In Thousands)</i> | | | | |
| GAAP Total Revenues | \$ 255,965 | \$ 240,670 | \$ 1,041,179 | \$ 882,060 |
| Revenue Growth | <u>6.4%</u> | | <u>18.0%</u> | |
| Adjustments: | | | | |
| Revenue associated with acquisitions | (14,699) | - | (175,391) | - |
| Revenues associated with divested brands | - | (116) | - | (23,021) |
| Non-GAAP Organic Revenues | \$ 241,266 | \$ 240,554 | \$ 865,788 | \$ 859,039 |
| Non-GAAP Organic Revenue Growth | <u>0.3%</u> | | <u>0.8%</u> | |
| Non-GAAP Organic Revenues | \$ 241,266 | \$ 240,554 | \$ 865,788 | \$ 859,039 |
| Revenues associated with acquisitions | 14,699 | 9,464 | 175,391 | 164,966 |
| Non-GAAP Proforma Revenues | \$ 255,965 | \$ 250,018 | \$ 1,041,179 | \$ 1,024,005 |
| Non-GAAP Proforma Revenue Growth | <u>2.4%</u> | | <u>1.7%</u> | |

Projected Free Cash Flow

| | 2019 Projected Free Cash Flow |
|--|----------------------------------|
| <i>(In millions)</i> | |
| Projected FY'19 GAAP Net cash provided by operating activities | \$ 228 |
| Additions to property and equipment for cash | (13) |
| Projected Non-GAAP Free Cash Flow | <u>\$ 215</u> |

Reconciliation Schedules Cont'd

Adjusted Free Cash Flow

| | Three Months Ended Mar. 31, | | Year Ended Mar. 31, | |
|---|-----------------------------|-----------|---------------------|------------|
| | 2018 | 2017 | 2018 | 2017 |
| <i>(In Thousands)</i> | | | | |
| GAAP Net Income (Loss) | \$ (39,687) | \$ 11,090 | \$ 339,570 | \$ 69,395 |
| Adjustments: | | | | |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities as shown in the Statement of Cash Flows | 103,215 | 21,447 | (113,698) | 92,613 |
| Changes in operating assets and liabilities, net of effects from acquisitions as shown in the Statement of Cash Flows | (9,090) | (25,013) | (15,762) | (13,336) |
| Total Adjustments | 94,125 | (3,566) | (129,460) | 79,277 |
| GAAP Net cash provided by operating activities | 54,438 | 7,524 | 210,110 | 148,672 |
| Purchase of property and equipment | (2,876) | (1,042) | (12,532) | (2,977) |
| Non-GAAP Free Cash Flow | 51,562 | 6,482 | 197,578 | 145,695 |
| Integration, transition and other payments associated with acquisitions and divestitures | 221 | 8,304 | 10,358 | 10,448 |
| Additional expense as a result of Term Loan debt refinancing | 182 | 9,184 | 182 | 9,184 |
| Pension contribution | - | 6,000 | - | 6,000 |
| Additional income tax payments associated with divestitures | - | 16,956 | - | 25,545 |
| Non-GAAP Adjusted Free Cash Flow | \$ 51,965 | \$ 46,926 | \$ 208,118 | \$ 196,872 |

Reconciliation Schedules Cont'd

Adjusted Net Income and Adjusted EPS

| | Three Months Ended Mar. 31, | | | | Year Ended Mar. 31, | | | |
|---|-----------------------------|----------------|------------------|----------------|---------------------|----------------|-------------------|----------------|
| | 2018 | | 2017 | | 2018 | | 2017 | |
| | Net Income | EPS | Net Income | EPS | Net Income | EPS | Net Income | EPS |
| <i>(In Thousands, except per share data)</i> | | | | | | | | |
| GAAP Net Income (Loss) | \$ (39,687) | \$ (0.74) | \$ 11,090 | \$ 0.21 | \$ 339,570 | \$ 6.34 | \$ 69,395 | \$ 1.30 |
| Adjustments: | | | | | | | | |
| Inventory step-up charges and other costs associated with acquisitions | - | - | 1,664 | 0.03 | - | - | 1,664 | 0.03 |
| Integration, transition and other costs associated with acquisitions and divestitures in Cost of Goods Sold | - | - | 1,367 | 0.03 | 3,719 | 0.07 | 1,367 | 0.03 |
| Integration, transition and other costs associated with acquisitions and divestitures in Advertising and Promotion Expense | - | - | 2,242 | 0.04 | (192) | - | 2,242 | 0.04 |
| Integration, transition and other costs associated with acquisitions and divestitures in General and Administrative Expense | 124 | - | 9,187 | 0.17 | 2,001 | 0.04 | 16,015 | 0.30 |
| Tax adjustment associated with acquisition in General and Administrative Expense | - | - | - | - | 704 | 0.01 | - | - |
| Accelerated amortization of debt origination costs | 392 | 0.01 | 575 | 0.01 | 392 | 0.01 | 1,706 | 0.03 |
| Additional expense as a result of Term Loan debt refinancing | 270 | - | 9,184 | 0.17 | 270 | - | 9,184 | 0.17 |
| Tradename impairment | 99,924 | 1.87 | - | - | 99,924 | 1.87 | - | - |
| Loss on extinguishment of debt | 2,901 | 0.05 | 1,420 | 0.03 | 2,901 | 0.05 | 1,420 | 0.03 |
| Loss on divestitures | - | - | 268 | 0.01 | - | - | 51,820 | 0.97 |
| Tax impact of adjustments | (36,574) | (0.68) | (9,438) | (0.18) | (38,804) | (0.72) | (28,024) | (0.53) |
| Normalized tax rate adjustment | 5,679 | 0.11 | 1,278 | 0.02 | (272,201) | (5.09) | (199) | - |
| Total Adjustments | 72,716 | 1.36 | 17,747 | 0.33 | (201,286) | (3.76) | 57,195 | 1.07 |
| Non-GAAP Adjusted Net Income and Adjusted EPS | \$ 33,029 | \$ 0.62 | \$ 28,837 | \$ 0.54 | \$ 138,284 | \$ 2.58 | \$ 126,590 | \$ 2.37 |

Note: Reported GAAP is calculated using diluted shares outstanding. Diluted shares outstanding for the three months ended March 31, 2018 are 53,512

Reconciliation Schedules Cont'd

Adjusted Free Cash Flow

| | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|--|------------------|-------------------|-------------------|------------------|-------------------|-------------------|-------------------|
| GAAP Net Income | \$ 37,212 | \$ 65,505 | \$ 72,615 | \$ 78,260 | \$ 99,907 | \$ 69,395 | \$ 339,570 |
| Adjustments | | | | | | | |
| Adjustments to reconcile net income to net cash provided by operating activities as shown in the statement of cash flows | 35,674 | 59,497 | 52,562 | 65,998 | 98,181 | 92,613 | (113,698) |
| Changes in operating assets and liabilities, net of effects from acquisitions as shown in the statement of cash flows | (5,434) | 12,603 | (11,945) | 13,327 | (21,778) | (13,336) | (15,762) |
| Total adjustments | 30,240 | 72,100 | 40,617 | 79,325 | 76,403 | 79,277 | (129,460) |
| GAAP Net cash provided by operating activities | 67,452 | 137,605 | 113,232 | 157,585 | 176,310 | 148,672 | 210,110 |
| Purchases of property and equipment | (606) | (10,268) | (2,764) | (6,101) | (3,568) | (2,977) | (12,532) |
| Non-GAAP Free Cash Flow | 66,846 | 127,337 | 110,468 | 151,484 | 172,742 | 145,695 | 197,578 |
| Premium payment on 2010 Senior Notes | - | - | 15,527 | - | - | - | - |
| Premium payment on extinguishment of 2012 Senior Notes | - | - | - | - | 10,158 | - | - |
| Accelerated payments due to debt refinancing | - | - | 4,675 | - | - | 9,184 | 182 |
| Integration, transition and other payments associated with acquisitions | - | - | 512 | 13,563 | 2,461 | 10,448 | 10,358 |
| Pension contribution | - | - | - | - | - | 6,000 | - |
| Additional income tax payments associated with divestitures | - | - | - | - | - | 25,545 | - |
| Total adjustments | - | - | 20,714 | 13,563 | 12,619 | 51,177 | 10,540 |
| Non-GAAP Adjusted Free Cash Flow | \$ 66,846 | \$ 127,337 | \$ 131,182 | \$165,047 | \$ 185,361 | \$ 196,872 | \$ 208,118 |

Dollar values in thousands.

Reconciliation Schedules Cont'd

Adjusted Net Income and Adjusted EPS

| | 2012 | | 2013 | | 2014 | | 2015 | | 2016 | | 2017 | | 2018 | |
|--|------------------|---------------|------------------|----------------|------------------|----------------|------------------|----------------|------------------|----------------|------------------|----------------|-------------------|----------------|
| | Net Income | EPS | Net Income | EPS | Net Income | EPS | Net Income | EPS | Net Income | EPS | Net Income | EPS | Net Income | EPS |
| GAAP Net Income | \$ 37,212 | \$0.73 | \$ 65,505 | \$ 1.27 | \$ 72,615 | \$ 1.39 | \$ 78,260 | \$ 1.49 | \$ 99,907 | \$ 1.88 | \$ 69,395 | \$ 1.30 | \$ 339,570 | \$ 6.34 |
| Adjustments | | | | | | | | | | | | | | |
| Additional expense as a result of Term Loan debt refinancing | - | - | - | - | - | - | - | - | - | - | 9,184 | 0.17 | 270 | - |
| Sales costs related to acquisitions | - | - | 411 | 0.01 | - | - | - | - | - | - | - | - | - | - |
| Inventory step up | 1,795 | 0.04 | 23 | - | 577 | 0.01 | 2,225 | 0.04 | 1,387 | 0.03 | 1,664 | 0.03 | - | - |
| Inventory related acquisition costs | - | - | 220 | - | 407 | 0.01 | - | - | - | - | - | - | - | - |
| Add'l supplier costs | - | - | 5,426 | 0.11 | - | - | - | - | - | - | - | - | - | - |
| Costs associated with CEO transition | - | - | - | - | - | - | - | - | 1,406 | 0.02 | - | - | - | - |
| Integration, Transition, and other Acquisition/Divestiture costs | 17,395 | 0.34 | 5,909 | 0.11 | 1,111 | 0.02 | 21,507 | 0.41 | 2,401 | 0.05 | 19,624 | 0.37 | 5,528 | 0.11 |
| Stamp Duty | - | - | - | - | - | - | 2,940 | 0.05 | - | - | - | - | - | - |
| Unsolicited proposal costs | 1,737 | 0.03 | 534 | 0.01 | - | - | - | - | - | - | - | - | - | - |
| Loss on extinguishment of debt | 5,409 | 0.11 | 1,443 | 0.03 | 18,286 | 0.35 | - | - | 17,970 | 0.34 | 1,420 | 0.03 | 2,901 | 0.05 |
| Gain on settlement | (5,063) | (0.10) | - | - | - | - | - | - | - | - | - | - | - | - |
| (Gain) loss on divestitures | - | - | - | - | - | - | (1,133) | (0.02) | - | - | 51,820 | 0.97 | - | - |
| Accelerated amortization of debt discounts and debt issue costs | - | - | 7,746 | 0.15 | 5,477 | 0.10 | 218 | - | - | - | 1,706 | 0.03 | 392 | 0.01 |
| Tradename impairment | - | - | - | - | - | - | - | - | - | - | - | - | 99,924 | 1.87 |
| Tax adj. associated with acquisition in G&A expense | - | - | - | - | - | - | - | - | - | - | - | - | 704 | 0.01 |
| Tax impact on adjustments | (8,091) | (0.16) | (8,329) | (0.16) | (9,100) | (0.17) | (5,968) | (0.11) | (7,608) | (0.15) | (28,024) | (0.52) | (38,804) | (0.72) |
| Normalized tax rate adjustment | (237) | - | (1,741) | (0.03) | (9,465) | (0.18) | - | - | - | - | (199) | - | (272,201) | (5.09) |
| Total adjustments | 12,945 | 0.26 | 11,642 | 0.23 | 7,293 | 0.14 | 19,789 | 0.37 | 15,556 | 0.29 | 57,195 | 1.07 | (201,286) | (3.76) |
| Non-GAAP Adjusted Net Income and Non-GAAP Adjusted EPS | \$50,157 | \$0.99 | \$ 77,147 | \$ 1.50 | \$79,908 | \$ 1.53 | \$98,049 | \$ 1.86 | \$115,463 | \$ 2.17 | \$126,590 | \$ 2.37 | \$138,284 | \$ 2.58 |

Dollar values in thousands, except per share data

Note: Reported GAAP is calculated using diluted shares outstanding. Diluted shares outstanding for the three months ended March 31, 2018 are 53,512

Reconciliation Schedules Cont'd

| | Adjusted EBITDA | | | | | | |
|--|------------------|-------------------|------------------|-------------------|-------------------|------------------|-------------------|
| | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
| GAAP Net Income (Loss) | \$ 37,212 | \$ 65,505 | \$ 72,615 | \$ 78,260 | \$ 99,907 | \$ 69,395 | \$ 339,570 |
| Interest Expense, net | 41,320 | 84,407 | 68,582 | 81,234 | 85,160 | 93,343 | 105,879 |
| Provision (benefit) for income taxes | 23,945 | 40,529 | 29,133 | 49,198 | 57,278 | 41,455 | (232,484) |
| Depreciation and amortization | 10,734 | 13,235 | 13,486 | 17,740 | 23,676 | 25,792 | 33,426 |
| Non-GAAP EBITDA | 113,211 | 203,676 | 183,816 | 226,432 | 266,021 | 229,985 | 246,391 |
| Sales costs related to acquisitions | - | 411 | - | - | - | - | - |
| Inventory step up | 1,795 | 23 | 577 | 2,225 | 1,387 | 1,664 | - |
| Inventory related acquisition costs | - | 220 | 407 | - | - | - | - |
| Add'l supplier costs | - | 5,426 | - | - | - | - | - |
| Costs associated with CEO transition | - | - | - | - | 1,406 | - | - |
| Integration, transition, and other Acquisition/Divestiture costs | 17,395 | 5,909 | 1,111 | 21,507 | 2,401 | 19,624 | 5,528 |
| Stamp Duty | - | - | - | 2,940 | - | - | - |
| Unsolicited proposal costs | 1,737 | 534 | - | - | - | - | - |
| Loss on extinguishment of debt | 5,409 | 1,443 | 18,286 | - | 17,970 | 1,420 | 2,901 |
| Tradename impairment | - | - | - | - | - | - | 99,924 |
| Gain on settlement | (5,063) | - | - | - | - | - | - |
| (Gain) Loss on divestitures | - | - | - | (1,133) | - | 51,820 | - |
| Tax adjustment associated with acquisitions | - | - | - | - | - | - | 704 |
| Adjustments to EBITDA | 21,273 | 13,966 | 20,381 | 25,539 | 23,164 | 74,528 | 109,057 |
| Non-GAAP Adjusted EBITDA | \$134,484 | \$ 217,642 | \$204,197 | \$ 251,971 | \$ 289,185 | \$304,513 | \$ 355,448 |

Dollar values in thousands.